Estuary Biotherapeutics, Inc. — SEC Form D Filing

Estuary Biotherapeutics, Inc. filed an SEC Form D on October 16, 2026, reporting $40.65M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
October 16, 2026
Amount reported
$40.65M
Round stage
Series A, aligned with the company's launch backed by a $93 million Series A commitment to advance early candidates into the clinic.
Industry
Biotechnology
Website
https://www.estuarybio.com

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Autosomal dominant polycystic kidney disease causes progressive renal failure without curative genetic treatments available to address its underlying mutations.

Solution

Estuary Biotherapeutics develops kidney-directed adeno-associated virus gene therapies designed to deliver functional genetic components to restore polycystin proteins.

Why now

Recent advancements in kidney-targeted viral capsid engineering enable precise gene delivery directly to renal cells that was previously unachievable.

Source: SEC EDGAR Form D filing